These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21574421)

  • 21. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
    Campbell JL; Fay MP; Lanning LL; Hewitt JA
    Clin Infect Dis; 2020 May; 70(70 Suppl 1):S60-S65. PubMed ID: 32435805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of cefixime and cefepime vs. other cephalosporins in experimental plague of albino mice due to variants FI+ and FI- of the plague microbe].
    Ryzhko IV; Shcherbaniuk AI; Moldavan IA; Tsuraeva RI; Anisimov BI; Trishina AV
    Antibiot Khimioter; 2007; 52(9-10):24-7. PubMed ID: 20583467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of the new quinolones, ciprofloxacin and pefloxacin in experimental plague].
    Kasatkina IV; Sherbaniuk AI; Makarovskaia LN; Padeĭskaia EN
    Antibiot Khimioter; 1993 Jan; 38(1):42-5. PubMed ID: 8060184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cefoperazone in the prevention and treatment of experimental plague caused by typical and fraction-free pathogen strains in white mice].
    Pasiukov VV; Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Roshchina NV
    Antibiot Khimioter; 1994 Aug; 39(8):37-40. PubMed ID: 7695439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
    Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
    Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
    Puig C; Tirado-Vélez JM; Calatayud L; Tubau F; Garmendia J; Ardanuy C; Marti S; de la Campa AG; Liñares J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):461-6. PubMed ID: 25385097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
    Russell P; Eley SM; Green M; Stagg AJ; Taylor RR; Nelson M; Beedham RJ; Bell DL; Rogers D; Whittington D; Titball RW
    J Antimicrob Chemother; 1998 Feb; 41(2):301-5. PubMed ID: 9533478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virulent non-capsulate Yersinia pestis variants constructed by insertion mutagenesis.
    Drozdov IG; Anisimov AP; Samoilova SV; Yezhov IN; Yeremin SA; Karlyshev AV; Krasilnikova VM; Kravchenko VI
    J Med Microbiol; 1995 Apr; 42(4):264-8. PubMed ID: 7707334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Doxycycline in the prevention of experimental plague induced by plague microbe variants].
    Samokhodkina ED; Ryzhko IV; Shcherbaniuk AI; Kasatkina IV; Tsuraeva RI; Zhigalova TA
    Antibiot Khimioter; 1992 Nov; 37(11):26-8. PubMed ID: 1300930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ceftriaxone in prevention and treatment of experimental plague infection].
    Ryzhko IV; Samokhodkina ED; Zhigalova TA
    Antibiot Khimioter; 1993 Jan; 38(1):39-42. PubMed ID: 8060183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibiotics of the aminoglycoside group (gentamicin, sisomicin and amikacin) in the prevention and treatment of experimental plague].
    Shcherbaniuk AI; Makarovskaia LN; Bugaeva OK; Kasatkina IV
    Antibiot Khimioter; 1992 May; 37(5):30-1. PubMed ID: 1417325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.
    Kadhiravan T; Wig N; Kapil A; Kabra SK; Renuka K; Misra A
    BMC Infect Dis; 2005 May; 5():37. PubMed ID: 15904505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of plague prophylaxis with streptomycin, tetracycline, and rifampicin in simultaneous immunization of white mice by resistant EV NRIEG strain].
    Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI
    Antibiot Khimioter; 2004; 49(1):17-21. PubMed ID: 15164519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.